Is 11 C-choline the most appropriate tracer for prostate cancer?
- 2 April 2004
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (5) , 756-759
- https://doi.org/10.1007/s00259-004-1543-8
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane AntigenJournal of Urology, 2003
- Magnetic Resonance Imaging and Spectroscopic Imaging of Prostate CancerJournal of Urology, 2003
- Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane AntigenJournal of Urology, 2003
- Advances in imaging in the postoperative patient with a rising prostate-specific antigen levelSeminars in Oncology, 2003
- Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasoundThe British Journal of Radiology, 2003
- Prostate Lymphoscintigraphy and Radio-Guided Surgery for Sentinel Lymph Node Identification in Prostate CancerUrologia Internationalis, 2003
- Indium-111–Capromab Pendetide Radioimmunoscintigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed ProstatectomyJournal of Clinical Oncology, 2003
- Value of [ 11 C]choline-Positron Emission Tomography for Re-Staging Prostate Cancer: A Comparison With [ 18 F]fluorodeoxyglucose-Positron Emission TomographyJournal of Urology, 2003
- Positive [11C]Choline and Negative [18F]FDG with Positron Emission Tomography in Recurrence of Prostate CancerAmerican Journal of Roentgenology, 2002
- Combating Prostate CancerScientific American, 1998